Expanded efficacy and safety data from CheckMate 649

Prof.  Markus Moehler speaks about CheckMate 649 trial (first-line nivolumab plus chemotherapy versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma).

Current state of frontline immunotherapy options in the treatment of NSCLC

Prof.  Federico Cappuzzo, Director of Medical Oncology in National Cancer Institute from Italy summarize the current state of frontline immunotherapy options in the treatment of NSCLC both in early stage and in metastatic advanced disease.

Clinical decision making in the treatment of melanoma

Prof. Ascierto speaks about the results of the recent ASCO 2021 novelties in the field of melanoma.

State of the art treatment of prostate cancer

Prof. Sartor speaks about the changes and progress we seen in prostate cancer treatment in the last couple of months.

State of the art treatment of breast cancer

Prof. Virginia Kaklamani gave us an update what she considered the most important abstract presented at this year's ASCO 2021.

State of the art treatment of multiple myeloma

Prof. Andrzej Jakubowiak speaks about the key updates from last ASCO meeting.

Current state of immunotherapy options in the treatment of RCC

Prof. Camillo Porta talks about the current state of immunotherapy options in the treatment of advanced metastatic renal cell cancer with regard to the ASCO 2021 meeting.

Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.

Prof. Veluswamy speaks about the updated results of the study.

Current state of immunotherapy options in the treatment of melanoma

Important results in melanoma treatment have been announced on ASCO 2021 meeting. Prof. Weber as a renowned expert of the field summarize the most important findings.

State of the art treatment of breast cancer

Prof. Jane Meisel speaks about Breast Cancer updates from ASCO 2021.

Response and survival results up to five years from the KEYNOTE-052 phase 2 study

First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial cancer.

Expanded efficacy and safety analyses from CheckMate 577

Prof. Kelly speaks about the results of the CheckMate 577 trial: adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy.

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer

Prof. Heather Wakelee speaks about the results of IMpower010 study.

Relatlimab plus nivolumab versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047

Prof. Evan Lipson speaks about the results of RELATIVITY-047 study.

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Dr. Emeline Colomba speaks about the results of ODENZA study.